GlassScriptPhysician profile
Gewon Shu
NPI 1982013843
$3,576.16
in general payments reported to CMS, 2019-2025
9 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.93 · 2020: $89.99 · 2021: $363 · 2022: $579 · 2023: $1,667 · 2024: $578 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,276 · Food and Beverage: $1,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,276.09 |
| Food and Beverage | $1,222.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,411.68 | 2019-2025 | Total30, Dailies Total1, Precision 1 |
| Johnson & Johnson Vision Care, INC. | $384.68 | 2019-2025 | Acuvue |
| Coopervision INC. | $219.93 | 2020-2024 | Myday Contact Lens |
| Biotissue Holdings INC. | $150.27 | 2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $137.40 | 2020-2021 | |
| Sight Sciences, INC. | $98.49 | 2022 | |
| Lkc Technologies, INC. | $94.53 | 2024 | |
| Astellas Pharma US INC | $49.97 | 2024 | Izervay |
| Bausch & Lomb Americas INC. | $29.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gewon Shu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.